RAPT Therapeutics Reports Fourth Quarter and Year End Financial Results Portfolio News / Karina Tin March 14, 2023 RAPT Therapeutics Reports Fourth Quarter and Year End Financial Results Read More »
Ribon Therapeutics Doses First Patient In Phase 1 Clinical Study with RBN-3143 in Patients with Moderate to Severe Atopic Dermatitis Portfolio News / Karina Tin March 9, 2023 Ribon Therapeutics Doses First Patient In Phase 1 Clinical Study with RBN-3143 in Patients with Moderate to Severe Atopic Dermatitis Read More »
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer Portfolio News / Karina Tin March 8, 2023 eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer Read More »
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Portfolio News / Karina Tin March 8, 2023 eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Read More »
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Portfolio News / Karina Tin March 8, 2023 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Read More »
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / Karina Tin March 7, 2023 Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More »
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results Portfolio News / Karina Tin February 28, 2023 NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results Read More »
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Portfolio News / Karina Tin February 27, 2023 Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Read More »
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID Portfolio News / Karina Tin February 21, 2023 eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID Read More »
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy Portfolio News / Karina Tin February 14, 2023 Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy Read More »